Normal view MARC view ISBD view

Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review. [Review]

MedStar author(s):

Citation: Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine. 22(3):69-82, 2023 09 01.PMID: 37363862Institution: MedStar Union Memorial HospitalDepartment: Internal Medicine ResidencyForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Myocarditis | *Neoplasms | *Pericarditis | Humans | Immune Checkpoint Inhibitors/ae [Adverse Effects] | Myocarditis/ci [Chemically Induced] | Myocarditis/di [Diagnosis] | Myocarditis/th [Therapy] | Neoplasms/dt [Drug Therapy] | Risk Factors | Year: 2023 ISSN:

1535-2811

Name of journal: Critical pathways in cardiologyAbstract: Immune checkpoint inhibitors (ICIs), a significant breakthrough treatment of cancer, exert their function through enhancing the immune system's ability to recognize and attack cancer cells. However, these revolutionary cancer treatments have been associated with a range of immune-related adverse effects, including cardiovascular toxicity. The most commonly reported cardiovascular toxicities associated with ICIs are myocarditis, pericarditis, arrhythmias, and vasculitis. These cardiovascular manifestations are often severe and can lead to life-threatening complications. Therefore, prompt identification and management of these toxicities is critical, and a multidisciplinary teamwork by cardiologists and oncologists are required to ensure optimal patient outcomes. In this review, we summarize the current knowledge on the mechanisms underlying ICI-associated cardiovascular toxicity, clinical presentations of these toxicities, potential risk factors, diagnosis, management, and surveillance strategies during ICI therapy. While ICIs have already transformed cancer treatment, further research is needed to better understand and manage their immune-related cardiovascular effects, and possibly, to identify biomarkers which can predict the occurrence of these cardiovascular complications. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.All authors: Chitsazan M, Amin A, Ladel L, Baig A, Chitsazan MFiscal year: FY2024 Digital Object Identifier:

https://dx.doi.org/10.1097/HPC.0000000000000327

Date added to catalog: 2023-11-22

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	37363862	Available		37363862

Immune checkpoint inhibitors (ICIs), a significant breakthrough treatment of cancer, exert their function through enhancing the immune system's ability to recognize and attack cancer cells. However, these revolutionary cancer treatments have been associated with a range of immune-related adverse effects, including cardiovascular toxicity. The most commonly reported cardiovascular toxicities associated with ICIs are myocarditis, pericarditis, arrhythmias, and vasculitis. These cardiovascular manifestations are often severe and can lead to life-threatening complications. Therefore, prompt identification and management of these toxicities is critical, and a multidisciplinary teamwork by cardiologists and oncologists are required to ensure optimal patient outcomes. In this review, we summarize the current knowledge on the mechanisms underlying ICI-associated cardiovascular toxicity, clinical presentations of these toxicities, potential risk factors, diagnosis, management, and surveillance strategies during ICI therapy. While ICIs have already transformed cancer treatment, further research is needed to better understand and manage their immune-related cardiovascular effects, and possibly, to identify biomarkers which can predict the occurrence of these cardiovascular complications. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

English